{
    "abstract": "Background: We evaluated the immunogenicity and safety of 1 and 2 doses of quadrivalent meningococcal serogroup A, C, W and Y tetanus toxoid-conjugate vaccine (MenACWY-TT) given alone or co-administered with 13-valent pneumococcal conjugate vaccine (PCV13) in toddlers. Methods: In this phase III, open-label, controlled, multicentre study (NCT01939158), healthy toddlers aged 12\u201314 months were randomised into 4 groups to receive 1 dose of MenACWY-TT at month (M) 0 (ACWY_1), 2 doses of MenACWY-TT at M0 and M2 (ACWY_2), MenACWY-TT and PCV13 at M0 (Co-ad), or PCV13 at M0 and MenACWY-TT at M2 (PCV13/ACWY). Immune responses were assessed 1 month post-each vaccination. Solicited and unsolicited symptoms were recorded for 4 and 31 days post-each vaccination, respectively; serious adverse events (SAEs) and new onset of chronic illnesses (NOCIs) up to M9 from first vaccination. Results: 802 toddlers were vaccinated. Post-dose 1 of MenACWY-TT, \u226592.8% of toddlers had rSBA titres \u22651:8, and \u226562.5% had hSBA titres \u22651:4 for each meningococcal serogroup. Post-dose 2 of MenACWY-TT, rSBA titres \u22651:8 were observed in \u226598.0% and hSBA titres \u22651:4 in \u226595.3% of toddlers. Percentages of toddlers with hSBA titres \u22651:4 were higher after 2 doses versus 1 dose of MenACWY-TT for MenW (97.1% versus 62.5\u201368.9%) and MenY (95.3% versus 64.3\u201367.6%). Non-inferiority of immune responses to co-administered MenACWY-TT and PCV13 over their separate administration was demonstrated. AEs incidence was comparable among groups. SAEs were reported for 4.9%, 5.1%, 5.5% and 7.5%, and NOCIs for 2.0%, 3.0%, 0.5% and 3.5% of toddlers in the ACWY_1, ACWY_2, Co-ad and PCV13/ACWY groups, respectively; 4 SAEs reported in 3 toddlers were vaccine-related. Two fatal vaccine-unrelated SAEs were reported. Conclusion: MenACWY-TT was immunogenic when administered as a single dose at 12\u201314 months of age. A second dose in toddlers increased hSBA responses against MenW and MenY. MenACWY-TT and PCV13 can be co-administered without impairing the immunogenicity or safety profile of either vaccine.",
    "author_highlights": [
        {
            "endOffset": 22771,
            "sentence": "1- and 2-dose schedules of MenACWY-TT were assessed in toddlers.",
            "startOffset": 22707
        },
        {
            "endOffset": 22847,
            "sentence": "Post-each dose, \u226592.8% of toddlers had rSBA titres \u22651:8 for each serogroup.",
            "startOffset": 22772
        },
        {
            "endOffset": 22923,
            "sentence": "Post-each dose, \u226562.5% of toddlers had hSBA titres \u22651:4 for each serogroup.",
            "startOffset": 22848
        },
        {
            "endOffset": 23009,
            "sentence": "rSBA/hSBA immune responses were improved after 2 vs 1 vaccine dose for MenY and MenW.",
            "startOffset": 22924
        },
        {
            "endOffset": 23094,
            "sentence": "Co-administration of MenACWY-TT and PCV13 had no impact on immunogenicity or safety.",
            "startOffset": 23010
        }
    ],
    "bib_entries": {
        "b0005": {
            "authors": [
                {
                    "first": "Federico",
                    "initial": "F.",
                    "last": "Martin\u00f3n-Torres"
                }
            ],
            "doi": "10.1016/j.jadohealth.2016.03.041",
            "firstpage": "S12",
            "issn": "1054139X",
            "lastpage": "S20",
            "pmid": "27449145",
            "pub_year": 2016,
            "title": "Deciphering the Burden of Meningococcal Disease: Conventional and Under-recognized Elements",
            "volume": "59"
        },
        "b0010": {
            "authors": [
                {
                    "first": "Peter B.",
                    "initial": "P.B.",
                    "last": "McIntyre"
                },
                {
                    "first": "Katherine L.",
                    "initial": "K.L.",
                    "last": "O'Brien"
                },
                {
                    "first": "Brian",
                    "initial": "B.",
                    "last": "Greenwood"
                },
                {
                    "first": "Diederik",
                    "initial": "D.",
                    "last": "Van De Beek"
                }
            ],
            "doi": "10.1016/S0140-6736(12)61187-8",
            "firstpage": "1703",
            "issn": "01406736",
            "lastpage": "1711",
            "pmid": "23141619",
            "pub_year": 2012,
            "title": "Effect of vaccines on bacterial meningitis worldwide",
            "volume": "380"
        },
        "b0015": {
            "authors": [
                {
                    "first": "Rabab Z.",
                    "initial": "R.Z.",
                    "last": "Jafri"
                },
                {
                    "first": "Asad",
                    "initial": "A.",
                    "last": "Ali"
                },
                {
                    "first": "Nancy E.",
                    "initial": "N.E.",
                    "last": "Messonnier"
                },
                {
                    "first": "Carol",
                    "initial": "C.",
                    "last": "Tevi-Benissan"
                },
                {
                    "first": "David",
                    "initial": "D.",
                    "last": "Durrheim"
                },
                {
                    "first": "Juhani",
                    "initial": "J.",
                    "last": "Eskola"
                },
                {
                    "first": "Florence",
                    "initial": "F.",
                    "last": "Fermon"
                },
                {
                    "first": "Keith P.",
                    "initial": "K.P.",
                    "last": "Klugman"
                },
                {
                    "first": "Mary",
                    "initial": "M.",
                    "last": "Ramsay"
                },
                {
                    "first": "Samba",
                    "initial": "S.",
                    "last": "Sow"
                },
                {
                    "first": "Shao",
                    "initial": "S.",
                    "last": "Zhujun"
                },
                {
                    "first": "Zulfiqar A.",
                    "initial": "Z.A.",
                    "last": "Bhutta"
                },
                {
                    "first": "Jon",
                    "initial": "J.",
                    "last": "Abramson"
                }
            ],
            "doi": "10.1186/1478-7954-11-17",
            "issn": "14787954",
            "pub_year": 2013,
            "title": "Global epidemiology of invasive meningococcal disease",
            "volume": "11"
        },
        "b0020": null,
        "b0025": {
            "authors": [
                {
                    "first": "Jay",
                    "initial": "J.",
                    "last": "Lucidarme"
                },
                {
                    "first": "Dorothea M.C.",
                    "initial": "D.M.C.",
                    "last": "Hill"
                },
                {
                    "first": "Holly B.",
                    "initial": "H.B.",
                    "last": "Bratcher"
                },
                {
                    "first": "Steve J.",
                    "initial": "S.J.",
                    "last": "Gray"
                },
                {
                    "first": "Mignon",
                    "initial": "M.",
                    "last": "du Plessis"
                },
                {
                    "first": "Raymond S.W.",
                    "initial": "R.S.W.",
                    "last": "Tsang"
                },
                {
                    "first": "Julio A.",
                    "initial": "J.A.",
                    "last": "Vazquez"
                },
                {
                    "first": "Muhamed Kheir",
                    "initial": "M.K.",
                    "last": "Taha"
                },
                {
                    "first": "Mehmet",
                    "initial": "M.",
                    "last": "Ceyhan"
                },
                {
                    "first": "Adriana M.",
                    "initial": "A.M.",
                    "last": "Efron"
                },
                {
                    "first": "Maria C.",
                    "initial": "M.C.",
                    "last": "Gorla"
                },
                {
                    "first": "Jamie",
                    "initial": "J.",
                    "last": "Findlow"
                },
                {
                    "first": "Keith A.",
                    "initial": "K.A.",
                    "last": "Jolley"
                },
                {
                    "first": "Martin C.J.",
                    "initial": "M.C.J.",
                    "last": "Maiden"
                },
                {
                    "first": "Ray",
                    "initial": "R.",
                    "last": "Borrow"
                }
            ],
            "doi": "10.1016/j.jinf.2015.07.007",
            "firstpage": "544",
            "issn": "01634453",
            "lastpage": "552",
            "pmid": "26226598",
            "pub_year": 2015,
            "title": "Genomic resolution of an aggressive, widespread, diverse and expanding meningococcal serogroup B, C and W lineage",
            "volume": "71"
        },
        "b0030": {
            "authors": [
                {
                    "first": "Mustapha M.",
                    "initial": "M.M.",
                    "last": "Mustapha"
                },
                {
                    "first": "Jane W.",
                    "initial": "J.W.",
                    "last": "Marsh"
                },
                {
                    "first": "Lee H.",
                    "initial": "L.H.",
                    "last": "Harrison"
                }
            ],
            "doi": "10.1016/j.vaccine.2016.02.014",
            "firstpage": "1515",
            "issn": "0264410X",
            "lastpage": "1523",
            "pmid": "26876439",
            "pub_year": 2016,
            "title": "Global epidemiology of capsular group W meningococcal disease (1970-2015): Multifocal emergence and persistence of hypervirulent sequence type (ST)-11 clonal complex",
            "volume": "34"
        },
        "b0035": {
            "authors": [
                {
                    "first": "Kylie S.",
                    "initial": "K.S.",
                    "last": "Carville"
                },
                {
                    "first": "Kerrie",
                    "initial": "K.",
                    "last": "Stevens"
                },
                {
                    "first": "Asma",
                    "initial": "A.",
                    "last": "Sohail"
                },
                {
                    "first": "Lucinda J.",
                    "initial": "L.J.",
                    "last": "Franklin"
                },
                {
                    "first": "Katherine A.",
                    "initial": "K.A.",
                    "last": "Bond"
                },
                {
                    "first": "Aicha",
                    "initial": "A.",
                    "last": "Brahmi"
                },
                {
                    "first": "Finn",
                    "initial": "F.",
                    "last": "Romanes"
                },
                {
                    "first": "Katherine S.",
                    "initial": "K.S.",
                    "last": "Ong"
                }
            ],
            "doi": "10.3201/eid2210.151935",
            "firstpage": "1785",
            "issn": "10806040",
            "lastpage": "1787",
            "pmid": "27648521",
            "pub_year": 2016,
            "title": "Increase in meningococcal serogroup W Disease, Victoria, Australia, 2013\u20132015",
            "volume": "22"
        },
        "b0040": {
            "authors": [
                {
                    "first": "Ameneh",
                    "initial": "A.",
                    "last": "Khatami"
                },
                {
                    "first": "Andrew J.",
                    "initial": "A.J.",
                    "last": "Pollard"
                }
            ],
            "doi": "10.1586/erv.10.3",
            "firstpage": "285",
            "issn": "14760584",
            "lastpage": "298",
            "pmid": "20218857",
            "pub_year": 2010,
            "title": "The epidemiology of meningococcal disease and the impact of vaccines",
            "volume": "9"
        },
        "b0045": {
            "authors": [
                {
                    "first": "Jamie D.",
                    "initial": "J.D.",
                    "last": "Croxtall"
                },
                {
                    "first": "Sohita",
                    "initial": "S.",
                    "last": "Dhillon"
                }
            ],
            "doi": "10.2165/11209580-000000000-00000",
            "firstpage": "2407",
            "issn": "00126667",
            "lastpage": "2430",
            "pmid": "23231026",
            "pub_year": 2012,
            "title": "Meningococcal quadrivalent (Serogroups A, C, W135 and Y) tetanus toxoid conjugate vaccine (Nimenrix\u2122)",
            "volume": "72"
        },
        "b0050": {
            "authors": [
                {
                    "first": "Aia",
                    "initial": "A.",
                    "last": "Assaf-Casals"
                },
                {
                    "first": "Ghassan",
                    "initial": "G.",
                    "last": "Dbaibo"
                }
            ],
            "doi": "10.1080/21645515.2016.1143157",
            "firstpage": "1825",
            "issn": "21645515",
            "lastpage": "1837",
            "pmid": "26900984",
            "pub_year": 2016,
            "title": "Meningococcal quadrivalent tetanus toxoid conjugate vaccine (MenACWY-TT, Nimenrix\u2122): A review of its immunogenicity, safety, co-administration, and antibody persistence",
            "volume": "12"
        },
        "b0055": {
            "authors": [
                {
                    "first": "Jose Manuel",
                    "initial": "J.M.",
                    "last": "Merino Arribas"
                },
                {
                    "first": "Alfonso",
                    "initial": "A.",
                    "last": "Carmona Mart\u00ednez"
                },
                {
                    "first": "Michael",
                    "initial": "M.",
                    "last": "Horn"
                },
                {
                    "first": "Xavier Maria",
                    "initial": "X.M.",
                    "last": "Perez Porcuna"
                },
                {
                    "first": "Maria Del Carmen",
                    "initial": "M.D.C.",
                    "last": "Otero Reigada"
                },
                {
                    "first": "Josep",
                    "initial": "J.",
                    "last": "Mar\u00e8s Berm\u00fadez"
                },
                {
                    "first": "Fernando",
                    "initial": "F.",
                    "last": "Centeno Malfaz"
                },
                {
                    "first": "Mariano",
                    "initial": "M.",
                    "last": "Miranda"
                },
                {
                    "first": "Maria",
                    "initial": "M.",
                    "last": "Mendez"
                },
                {
                    "first": "Miguel Angel",
                    "initial": "M.A.",
                    "last": "Garcia Cabezas"
                },
                {
                    "first": "Christoph",
                    "initial": "C.",
                    "last": "Wittermann"
                },
                {
                    "first": "Gerhard",
                    "initial": "G.",
                    "last": "Bleckmann"
                },
                {
                    "first": "Thomas",
                    "initial": "T.",
                    "last": "Fischbach"
                },
                {
                    "first": "Devayani",
                    "initial": "D.",
                    "last": "Kolhe"
                },
                {
                    "first": "Marie",
                    "initial": "M.",
                    "last": "Van Der Wielen"
                },
                {
                    "first": "Yaela",
                    "initial": "Y.",
                    "last": "Baine"
                }
            ],
            "doi": "10.1097/INF.0000000000001484",
            "firstpage": "e98",
            "issn": "08913668",
            "lastpage": "e107",
            "pmid": "28002359",
            "pub_year": 2017,
            "title": "Safety and Immunogenicity of the Quadrivalent Meningococcal Serogroups A, C, W and Y Tetanus Toxoid Conjugate Vaccine Coadministered With Routine Childhood Vaccines in European Infants: An Open, Randomized Trial",
            "volume": "36"
        },
        "b0060": {
            "authors": [
                {
                    "first": "Nicola P.",
                    "initial": "N.P.",
                    "last": "Klein"
                },
                {
                    "first": "Yaela",
                    "initial": "Y.",
                    "last": "Baine"
                },
                {
                    "first": "Veronique",
                    "initial": "V.",
                    "last": "Bianco"
                },
                {
                    "first": "Pascal R.",
                    "initial": "P.R.",
                    "last": "Lestrate"
                },
                {
                    "first": "Aftab",
                    "initial": "A.",
                    "last": "Naz"
                },
                {
                    "first": "Mark",
                    "initial": "M.",
                    "last": "Blatter"
                },
                {
                    "first": "Leonard R.",
                    "initial": "L.R.",
                    "last": "Friedland"
                },
                {
                    "first": "Jacqueline M.",
                    "initial": "J.M.",
                    "last": "Miller"
                }
            ],
            "doi": "10.1097/INF.0b013e31828693c5",
            "firstpage": "760",
            "issn": "08913668",
            "lastpage": "767",
            "pmid": "23348814",
            "pub_year": 2013,
            "title": "One or two doses of quadrivalent meningococcal serogroups A, C, W-135 and y tetanus toxoid conjugate vaccine is immunogenic in 9-to 12-month-old children",
            "volume": "32"
        },
        "b0065": {
            "authors": [
                {
                    "first": "M.",
                    "initial": "M.",
                    "last": "Knuf"
                },
                {
                    "first": "D.",
                    "initial": "D.",
                    "last": "Kieninger-Baum"
                },
                {
                    "first": "P.",
                    "initial": "P.",
                    "last": "Habermehl"
                },
                {
                    "first": "P.",
                    "initial": "P.",
                    "last": "Muttonen"
                },
                {
                    "first": "H.",
                    "initial": "H.",
                    "last": "Maurer"
                },
                {
                    "first": "P.",
                    "initial": "P.",
                    "last": "Vink"
                },
                {
                    "first": "J.",
                    "initial": "J.",
                    "last": "Poolman"
                },
                {
                    "first": "D.",
                    "initial": "D.",
                    "last": "Boutriau"
                }
            ],
            "doi": "10.1016/j.vaccine.2009.10.064",
            "firstpage": "744",
            "issn": "0264410X",
            "lastpage": "753",
            "pmid": "19887137",
            "pub_year": 2010,
            "title": "A dose-range study assessing immunogenicity and safety of one dose of a new candidate meningococcal serogroups A, C, W-135, Y tetanus toxoid conjugate (MenACWY-TT) vaccine administered in the second year of life and in young children",
            "volume": "28"
        },
        "b0070": {
            "authors": [
                {
                    "first": "Markus",
                    "initial": "M.",
                    "last": "Knuf"
                },
                {
                    "first": "Anna",
                    "initial": "A.",
                    "last": "Pantazi-Chatzikonstantinou"
                },
                {
                    "first": "Ulrich",
                    "initial": "U.",
                    "last": "Pfletschinger"
                },
                {
                    "first": "Irmingard",
                    "initial": "I.",
                    "last": "Tichmann-Schumann"
                },
                {
                    "first": "Hartwig",
                    "initial": "H.",
                    "last": "Maurer"
                },
                {
                    "first": "Lothar",
                    "initial": "L.",
                    "last": "Maurer"
                },
                {
                    "first": "Thomas",
                    "initial": "T.",
                    "last": "Fischbach"
                },
                {
                    "first": "Henrike",
                    "initial": "H.",
                    "last": "Zinke"
                },
                {
                    "first": "Heidemarie",
                    "initial": "H.",
                    "last": "Pankow-Culot"
                },
                {
                    "first": "Vassiliki",
                    "initial": "V.",
                    "last": "Papaevangelou"
                },
                {
                    "first": "Veronique",
                    "initial": "V.",
                    "last": "Bianco"
                },
                {
                    "first": "Marie",
                    "initial": "M.",
                    "last": "Van der Wielen"
                },
                {
                    "first": "Jacqueline M.",
                    "initial": "J.M.",
                    "last": "Miller"
                }
            ],
            "doi": "10.1016/j.vaccine.2011.03.009",
            "firstpage": "4264",
            "issn": "0264410X",
            "lastpage": "4273",
            "pmid": "21420417",
            "pub_year": 2011,
            "title": "An investigational tetravalent meningococcal serogroups A, C, W-135 and Y-tetanus toxoid conjugate vaccine co-administered with Infanrix\u2122 hexa is immunogenic, with an acceptable safety profile in 12-23-month-old children",
            "volume": "29"
        },
        "b0075": {
            "authors": [
                {
                    "first": "Ziad A.",
                    "initial": "Z.A.",
                    "last": "Memish"
                },
                {
                    "first": "Ghassan",
                    "initial": "G.",
                    "last": "Dbaibo"
                },
                {
                    "first": "May",
                    "initial": "M.",
                    "last": "Montellano"
                },
                {
                    "first": "Valsan P.",
                    "initial": "V.P.",
                    "last": "Verghese"
                },
                {
                    "first": "Hemant",
                    "initial": "H.",
                    "last": "Jain"
                },
                {
                    "first": "A. P.",
                    "initial": "A.P.",
                    "last": "Dubey"
                },
                {
                    "first": "Veronique",
                    "initial": "V.",
                    "last": "Bianco"
                },
                {
                    "first": "Marie",
                    "initial": "M.",
                    "last": "Van der Wielen"
                },
                {
                    "first": "Salvacion",
                    "initial": "S.",
                    "last": "Gatchalian"
                },
                {
                    "first": "Jacqueline M.",
                    "initial": "J.M.",
                    "last": "Miller"
                }
            ],
            "doi": "10.1097/INF.0b013e31820e6e02",
            "firstpage": "e56",
            "issn": "08913668",
            "lastpage": "e62",
            "pmid": "21278617",
            "pub_year": 2011,
            "title": "Immunogenicity of a single dose of tetravalent meningococcal serogroups a, c, w-135, and y conjugate vaccine administered to 2- to 10-year-olds is noninferior to a licensed-acwy polysaccharide vaccine with an acceptable safety profile",
            "volume": "30"
        },
        "b0080": {
            "authors": [
                {
                    "first": "Timo",
                    "initial": "T.",
                    "last": "Vesikari"
                },
                {
                    "first": "Aino",
                    "initial": "A.",
                    "last": "Karvonen"
                },
                {
                    "first": "Veronique",
                    "initial": "V.",
                    "last": "Bianco"
                },
                {
                    "first": "Marie",
                    "initial": "M.",
                    "last": "Van der Wielen"
                },
                {
                    "first": "Jacqueline",
                    "initial": "J.",
                    "last": "Miller"
                }
            ],
            "doi": "10.1016/j.vaccine.2011.03.043",
            "firstpage": "4274",
            "issn": "0264410X",
            "lastpage": "4284",
            "pmid": "21443965",
            "pub_year": 2011,
            "title": "Tetravalent meningococcal serogroups A, C, W-135 and Y conjugate vaccine is well tolerated and immunogenic when co-administered with measles-mumps-rubella-varicella vaccine during the second year of life: An open, randomized controlled trial",
            "volume": "29"
        },
        "b0085": {
            "authors": [
                {
                    "first": "Nicola P.",
                    "initial": "N.P.",
                    "last": "Klein"
                },
                {
                    "first": "Yaela",
                    "initial": "Y.",
                    "last": "Baine"
                },
                {
                    "first": "Devayani",
                    "initial": "D.",
                    "last": "Kolhe"
                },
                {
                    "first": "Carmen I.",
                    "initial": "C.I.",
                    "last": "Baccarini"
                },
                {
                    "first": "Jacqueline M.",
                    "initial": "J.M.",
                    "last": "Miller"
                },
                {
                    "first": "Marie",
                    "initial": "M.",
                    "last": "Van Der Wielen"
                }
            ],
            "doi": "10.1097/INF.0000000000001123",
            "firstpage": "662",
            "issn": "08913668",
            "lastpage": "672",
            "pmid": "26928521",
            "pub_year": 2016,
            "title": "Five-year antibody persistence and booster response after 1 or 2 doses of meningococcal A, C, W and y tetanus toxoid conjugate vaccine in healthy children",
            "volume": "35"
        },
        "b0090": {
            "authors": [
                {
                    "first": "Markus",
                    "initial": "M.",
                    "last": "Knuf"
                },
                {
                    "first": "Yaela",
                    "initial": "Y.",
                    "last": "Baine"
                },
                {
                    "first": "V\u00e9ronique",
                    "initial": "V.",
                    "last": "Bianco"
                },
                {
                    "first": "Dominique",
                    "initial": "D.",
                    "last": "Boutriau"
                },
                {
                    "first": "Jacqueline M.",
                    "initial": "J.M.",
                    "last": "Miller"
                }
            ],
            "doi": "10.4161/hv.20229",
            "firstpage": "866",
            "issn": "2164554X",
            "lastpage": "872",
            "pmid": "22485049",
            "pub_year": 2012,
            "title": "Antibody persistence and immune memory 15 months after priming with an investigational tetravalent meningococcal tetanus toxoid conjugate vaccine (MenACWY-TT) in toddlers and young children",
            "volume": "8"
        },
        "b0095": {
            "authors": [
                {
                    "first": "Timo",
                    "initial": "T.",
                    "last": "Vesikari"
                },
                {
                    "first": "Aino",
                    "initial": "A.",
                    "last": "Forsten"
                },
                {
                    "first": "Veronique",
                    "initial": "V.",
                    "last": "Bianco"
                },
                {
                    "first": "Marie",
                    "initial": "M.",
                    "last": "Van Der Wielen"
                },
                {
                    "first": "Jacqueline M.",
                    "initial": "J.M.",
                    "last": "Miller"
                }
            ],
            "doi": "10.1097/INF.0000000000000897",
            "firstpage": "e298",
            "issn": "08913668",
            "lastpage": "e307",
            "pmid": "26780033",
            "pub_year": 2015,
            "title": "Immunogenicity, safety and antibody persistence of a booster dose of quadrivalent meningococcal ACWY-tetanus toxoid conjugate vaccine compared with monovalent meningococcal Serogroup C vaccine administered four years after primary vaccination using the same vaccines",
            "volume": "34"
        },
        "b0100": {
            "authors": [
                {
                    "first": "Timo",
                    "initial": "T.",
                    "last": "Vesikari"
                },
                {
                    "first": "Aino",
                    "initial": "A.",
                    "last": "Forsten"
                },
                {
                    "first": "Veronique",
                    "initial": "V.",
                    "last": "Bianco"
                },
                {
                    "first": "Marie",
                    "initial": "M.",
                    "last": "Van Der Wielen"
                },
                {
                    "first": "Jacqueline M.",
                    "initial": "J.M.",
                    "last": "Miller"
                }
            ],
            "doi": "10.1080/21645515.2015.1058457",
            "firstpage": "132",
            "issn": "21645515",
            "lastpage": "139",
            "pmid": "26575983",
            "pub_year": 2016,
            "title": "Antibody persistence up to 5 years after vaccination of toddlers and children between 12 months and 10 years of age with a quadrivalent meningococcal ACWY-tetanus toxoid conjugate vaccine",
            "volume": "12"
        },
        "b0105": {
            "authors": [
                {
                    "first": "Timo",
                    "initial": "T.",
                    "last": "Vesikari"
                },
                {
                    "first": "Aino",
                    "initial": "A.",
                    "last": "Forst\u00e9n"
                },
                {
                    "first": "Dominique",
                    "initial": "D.",
                    "last": "Boutriau"
                },
                {
                    "first": "V\u00e9ronique",
                    "initial": "V.",
                    "last": "Bianco"
                },
                {
                    "first": "Marie",
                    "initial": "M.",
                    "last": "Van Der Wielen"
                },
                {
                    "first": "Jacqueline",
                    "initial": "J.",
                    "last": "Miller"
                }
            ],
            "doi": "10.4161/hv.22166",
            "firstpage": "1892",
            "issn": "21645515",
            "lastpage": "1903",
            "pmid": "23032159",
            "pub_year": 2012,
            "title": "Randomized trial to assess the immunogenicity, safety and antibody persistence up to three years after a single dose of a tetravalent meningococcal serogroups A, C, W-135 and Y tetanus toxoid conjugate vaccine in toddlers",
            "volume": "8"
        },
        "b0110": null,
        "b0115": {
            "authors": [
                {
                    "first": "I.",
                    "initial": "I.",
                    "last": "Goldschneider"
                },
                {
                    "first": "E. C.",
                    "initial": "E.C.",
                    "last": "Gotschlich"
                },
                {
                    "first": "M. S.",
                    "initial": "M.S.",
                    "last": "Artenstein"
                }
            ],
            "doi": "10.1084/jem.129.6.1307",
            "firstpage": "1307",
            "issn": "00221007",
            "lastpage": "1326",
            "pmid": "4977280",
            "pub_year": 1969,
            "title": "Human immunity to the meningococcus. I. The role of humoral antibodies.",
            "volume": "129"
        },
        "b0120": {
            "authors": [
                {
                    "first": "N. F.",
                    "initial": "N.F.",
                    "last": "Concepcion"
                },
                {
                    "first": "C. E.",
                    "initial": "C.E.",
                    "last": "Frasch"
                }
            ],
            "doi": "10.1128/CDLI.8.2.266-272.2001",
            "firstpage": "266",
            "issn": "1071412X",
            "lastpage": "272",
            "pmid": "11238206",
            "pub_year": 2001,
            "title": "Pneumococcal type 22F polysaccharide absorption improves the specificity of a pneumococcal-polysaccharide enzyme-linked immunosorbent assay",
            "volume": "8"
        },
        "b0125": {
            "authors": [
                {
                    "first": "Sandra",
                    "initial": "S.",
                    "last": "Romero-Steiner"
                },
                {
                    "first": "Daniel",
                    "initial": "D.",
                    "last": "Libutti"
                },
                {
                    "first": "Lorna B.",
                    "initial": "L.B.",
                    "last": "Pais"
                },
                {
                    "first": "Janet",
                    "initial": "J.",
                    "last": "Dykes"
                },
                {
                    "first": "Porter",
                    "initial": "P.",
                    "last": "Anderson"
                },
                {
                    "first": "John C.",
                    "initial": "J.C.",
                    "last": "Whitin"
                },
                {
                    "first": "Harry L.",
                    "initial": "H.L.",
                    "last": "Keyserling"
                },
                {
                    "first": "George M.",
                    "initial": "G.M.",
                    "last": "Carlone"
                }
            ],
            "firstpage": "415",
            "issn": "1071412X",
            "lastpage": "422",
            "pmid": "9220157",
            "pub_year": 1997,
            "title": "Standardization of an opsonophagocytic assay for the measurement of functional antibody activity against Streptococcus pneumoniae using differentiated HL-60 cells",
            "volume": "4"
        },
        "b0130": {
            "authors": [
                {
                    "first": "Nick",
                    "initial": "N.",
                    "last": "Andrews"
                },
                {
                    "first": "Ray",
                    "initial": "R.",
                    "last": "Borrow"
                },
                {
                    "first": "Elizabeth",
                    "initial": "E.",
                    "last": "Miller"
                }
            ],
            "doi": "10.1128/CDLI.10.5.780-786.2003",
            "firstpage": "780",
            "issn": "1071412X",
            "lastpage": "786",
            "pmid": "12965904",
            "pub_year": 2003,
            "title": "Validation of serological correlate of protection for meningococcal C conjugate vaccine by using efficacy estimates from postlicensure surveillance in England",
            "volume": "10"
        },
        "b0135": {
            "authors": [
                {
                    "first": "Ray",
                    "initial": "R.",
                    "last": "Borrow"
                },
                {
                    "first": "Paul",
                    "initial": "P.",
                    "last": "Balmer"
                },
                {
                    "first": "Elizabeth",
                    "initial": "E.",
                    "last": "Miller"
                }
            ],
            "doi": "10.1016/j.vaccine.2005.01.051",
            "firstpage": "2222",
            "issn": "0264410X",
            "lastpage": "2227",
            "pmid": "15755600",
            "pub_year": 2005,
            "title": "Meningococcal surrogates of protection - Serum bactericidal antibody activity",
            "volume": "23"
        },
        "b0140": {
            "authors": [
                {
                    "first": "Gianni",
                    "initial": "G.",
                    "last": "Bona"
                },
                {
                    "first": "Paolo",
                    "initial": "P.",
                    "last": "Castiglia"
                },
                {
                    "first": "Giorgio",
                    "initial": "G.",
                    "last": "Zoppi"
                },
                {
                    "first": "Maurizio",
                    "initial": "M.",
                    "last": "de Martino"
                },
                {
                    "first": "Annaelisa",
                    "initial": "A.",
                    "last": "Tasciotti"
                },
                {
                    "first": "Diego",
                    "initial": "D.",
                    "last": "D'Agostino"
                },
                {
                    "first": "Linda",
                    "initial": "L.",
                    "last": "Han"
                },
                {
                    "first": "Igor",
                    "initial": "I.",
                    "last": "Smolenov"
                }
            ],
            "doi": "10.1016/j.vaccine.2016.05.009",
            "firstpage": "3363",
            "issn": "0264410X",
            "lastpage": "3370",
            "pmid": "27181507",
            "pub_year": 2016,
            "title": "Safety and immunogenicity of a CRM or TT conjugated meningococcal vaccine in healthy toddlers",
            "volume": "34"
        },
        "b0145": {
            "authors": [
                {
                    "first": "Kate L.",
                    "initial": "K.L.",
                    "last": "Seib"
                },
                {
                    "first": "Maria",
                    "initial": "M.",
                    "last": "Scarselli"
                },
                {
                    "first": "Maurizio",
                    "initial": "M.",
                    "last": "Comanducci"
                },
                {
                    "first": "Daniela",
                    "initial": "D.",
                    "last": "Toneatto"
                },
                {
                    "first": "Vega",
                    "initial": "V.",
                    "last": "Masignani"
                }
            ],
            "doi": "10.1586/14760584.2015.1016915",
            "firstpage": "841",
            "issn": "14760584",
            "lastpage": "859",
            "pmid": "25704037",
            "pub_year": 2015,
            "title": "Neisseria meningitidis factor H-binding protein fHbp: Key virulence factor and vaccine antigen",
            "volume": "14"
        },
        "b0150": {
            "authors": [
                {
                    "first": "S. A.",
                    "initial": "S.A.",
                    "last": "Halperin"
                },
                {
                    "first": "F.",
                    "initial": "F.",
                    "last": "Diaz-Mitoma"
                },
                {
                    "first": "P.",
                    "initial": "P.",
                    "last": "Dull"
                },
                {
                    "first": "A.",
                    "initial": "A.",
                    "last": "Anemona"
                },
                {
                    "first": "F.",
                    "initial": "F.",
                    "last": "Ceddia"
                }
            ],
            "doi": "10.1007/s10096-009-0848-8",
            "firstpage": "259",
            "issn": "09349723",
            "lastpage": "267",
            "pmid": "20033465",
            "pub_year": 2010,
            "title": "Safety and immunogenicity of an investigational quadrivalent meningococcal conjugate vaccine after one or two doses given to infants and toddlers",
            "volume": "29"
        },
        "b0155": {
            "authors": [
                {
                    "first": "Miguel",
                    "initial": "M.",
                    "last": "Tregnaghi"
                },
                {
                    "first": "Pio",
                    "initial": "P.",
                    "last": "Lopez"
                },
                {
                    "first": "Daniel",
                    "initial": "D.",
                    "last": "Stamboulian"
                },
                {
                    "first": "Gabriela",
                    "initial": "G.",
                    "last": "Gra\u00f1a"
                },
                {
                    "first": "Tatjana",
                    "initial": "T.",
                    "last": "Odrljin"
                },
                {
                    "first": "Lisa",
                    "initial": "L.",
                    "last": "Bedell"
                },
                {
                    "first": "Peter M.",
                    "initial": "P.M.",
                    "last": "Dull"
                }
            ],
            "doi": "10.1016/j.ijid.2014.03.1390",
            "firstpage": "22",
            "issn": "12019712",
            "lastpage": "30",
            "pmid": "24980467",
            "pub_year": 2014,
            "title": "Immunogenicity and safety of a quadrivalent meningococcal polysaccharide CRM conjugate vaccine in infants and toddlers",
            "volume": "26"
        },
        "b0160": {
            "authors": [
                {
                    "first": "Guillermo M.",
                    "initial": "G.M.",
                    "last": "Ruiz-Palacios"
                },
                {
                    "first": "Li Min",
                    "initial": "L.M.",
                    "last": "Huang"
                },
                {
                    "first": "Tzou Yien",
                    "initial": "T.Y.",
                    "last": "Lin"
                },
                {
                    "first": "Lorena",
                    "initial": "L.",
                    "last": "Hernandez"
                },
                {
                    "first": "M.",
                    "initial": "M.",
                    "last": "Lourdes Guerrero"
                },
                {
                    "first": "Antonio Lavalle",
                    "initial": "A.L.",
                    "last": "Villalobos"
                },
                {
                    "first": "Marie",
                    "initial": "M.",
                    "last": "Van Der Wielen"
                },
                {
                    "first": "Marta",
                    "initial": "M.",
                    "last": "Moreira"
                },
                {
                    "first": "Laurence",
                    "initial": "L.",
                    "last": "Fissette"
                },
                {
                    "first": "Dorota",
                    "initial": "D.",
                    "last": "Borys"
                },
                {
                    "first": "Jacqueline M.",
                    "initial": "J.M.",
                    "last": "Miller"
                }
            ],
            "doi": "10.1097/INF.0b013e3182784143",
            "firstpage": "62",
            "issn": "08913668",
            "lastpage": "71",
            "pmid": "23076383",
            "pub_year": 2013,
            "title": "Immunogenicity and safety of a booster dose of the 10-valent pneumococcal haemophilus influenzae protein D conjugate vaccine coadministered with the tetravalent meningococcal serogroups A, C, W-135 and y tetanus toxoid conjugate vaccine in toddlers: A randomized trial",
            "volume": "32"
        },
        "b0165": {
            "authors": [
                {
                    "first": "Ron",
                    "initial": "R.",
                    "last": "Dagan"
                },
                {
                    "first": "Jan",
                    "initial": "J.",
                    "last": "Poolman"
                },
                {
                    "first": "Claire Anne",
                    "initial": "C.A.",
                    "last": "Siegrist"
                }
            ],
            "doi": "10.1016/j.vaccine.2010.06.026",
            "firstpage": "5513",
            "issn": "0264410X",
            "lastpage": "5523",
            "pmid": "20600514",
            "pub_year": 2010,
            "title": "Glycoconjugate vaccines and immune interference: A review",
            "volume": "28"
        },
        "b0170": {
            "authors": [
                {
                    "first": "Michael",
                    "initial": "M.",
                    "last": "Leonardi"
                },
                {
                    "first": "Thomas",
                    "initial": "T.",
                    "last": "Latiolais"
                },
                {
                    "first": "Kwabena",
                    "initial": "K.",
                    "last": "Sarpong"
                },
                {
                    "first": "Michael",
                    "initial": "M.",
                    "last": "Simon"
                },
                {
                    "first": "Jerry",
                    "initial": "J.",
                    "last": "Twiggs"
                },
                {
                    "first": "Paul",
                    "initial": "P.",
                    "last": "Lei"
                },
                {
                    "first": "Stephen",
                    "initial": "S.",
                    "last": "Rinderknecht"
                },
                {
                    "first": "Mark",
                    "initial": "M.",
                    "last": "Blatter"
                },
                {
                    "first": "Veronique",
                    "initial": "V.",
                    "last": "Bianco"
                },
                {
                    "first": "Yaela",
                    "initial": "Y.",
                    "last": "Baine"
                },
                {
                    "first": "Leonard R.",
                    "initial": "L.R.",
                    "last": "Friedland"
                },
                {
                    "first": "Jacqueline M.",
                    "initial": "J.M.",
                    "last": "Miller"
                }
            ],
            "doi": "10.1016/j.vaccine.2014.08.027",
            "firstpage": "933",
            "issn": "0264410X",
            "lastpage": "941",
            "pmid": "25152325",
            "pub_year": 2015,
            "title": "Quadrivalent meningococcal (MenACWY-TT) conjugate vaccine or a fourth dose of H. influenzae-N. meningitidis C/Y conjugate vaccine (HibMenCY-TT) is immunogenic in toddlers who previously received three doses of HibMenCY-TT in infancy",
            "volume": "33"
        },
        "b0175": {
            "authors": [
                {
                    "first": "Greg L.",
                    "initial": "G.L.",
                    "last": "Plosker"
                }
            ],
            "doi": "10.1007/s40272-013-0047-z",
            "firstpage": "403",
            "issn": "11745878",
            "lastpage": "423",
            "pmid": "24030738",
            "pub_year": 2013,
            "title": "13-valent pneumococcal conjugate vaccine: A review of its use in infants, children, and adolescents",
            "volume": "15"
        }
    },
    "body_text": [
        {
            "endOffset": 28946,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methods"
                }
            ],
            "secId": "s0015",
            "sentence": "Toddlers were randomised (1:1:1:1) into 4 groups to receive 1 dose of MenACWY-TT at month [M] 0 (ACWY_1 group), 2 doses of MenACWY-TT at M0 and M2 (ACWY_2 group), 1 dose of MenACWY-TT co-administered with PCV13 at M0 (Co-ad group), or 1 dose of PCV13 at M0 and 1 dose of MenACWY-TT at M2 (PCV13/ACWY group).",
            "startOffset": 28639,
            "title": "Study design and participants"
        },
        {
            "endOffset": 43644,
            "parents": [],
            "refoffsets": {
                "b0105": {
                    "endOffset": 43643,
                    "startOffset": 43639
                }
            },
            "secId": "s0065",
            "sentence": "The incidence of AEs observed in our study following vaccination with MenACWY-TT was similar to that previously reported in toddlers [21].",
            "startOffset": 43506,
            "title": "Discussion"
        },
        {
            "endOffset": 48323,
            "parents": [],
            "secId": "s0090",
            "sentence": "Prevenar/Prevenar 13 is a trademark of Pfizer.",
            "startOffset": 48277,
            "title": "Trademark statement"
        },
        {
            "endOffset": 25988,
            "parents": [],
            "secId": "s0005",
            "sentence": "The most important disease-causing serogroups are meningococcal serogroups A (MenA), MenB, MenC, MenW and MenY.",
            "startOffset": 25877,
            "title": "Introduction"
        },
        {
            "endOffset": 26761,
            "parents": [],
            "refoffsets": {
                "b0045": {
                    "endOffset": 26760,
                    "startOffset": 26754
                },
                "b0050": {
                    "endOffset": 26760,
                    "startOffset": 26754
                }
            },
            "secId": "s0005",
            "sentence": "MenACWY-TT has been approved for use as a single dose in individuals as of 12 months of age in Europe and Canada [9,10].",
            "startOffset": 26641,
            "title": "Introduction"
        },
        {
            "endOffset": 44762,
            "parents": [],
            "secId": "s0065",
            "sentence": "In addition, the open-label design might have biased the reporting of AE towards increasing frequencies in the Co-ad group.",
            "startOffset": 44639,
            "title": "Discussion"
        },
        {
            "endOffset": 30959,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methods"
                }
            ],
            "secId": "s0020",
            "sentence": "Other secondary objectives evaluated the immunogenicity, reactogenicity and safety of the study vaccines in all groups.",
            "startOffset": 30840,
            "title": "Objectives"
        },
        {
            "endOffset": 34245,
            "parents": [
                {
                    "id": "s0035",
                    "title": "Results"
                },
                {
                    "id": "s0045",
                    "title": "Immunogenicity"
                }
            ],
            "secId": "s0050",
            "sentence": "One month post-dose 1, percentages of toddlers with rSBA titres \u22651:8 in the ACWY_1 and ACWY_2 groups were \u226596.8% for MenA, \u226595.0% for MenC, \u226594.9% for MenW and \u226592.8% for MenY.",
            "startOffset": 34069,
            "title": "Immunogenicity of 1 or 2 doses of MenACWY-TT"
        },
        {
            "endOffset": 46612,
            "parents": [],
            "secId": "s0080",
            "sentence": "TN, SH, PR, HM, MH, DK and MvdW were involved in the design of the study; CLC, TN, SH, KA, KP, PR, HM, MH, MC collected the data; CLC, TN, SH, KA, PR, HM, MH, MC carried out the study, ZK, MC and DK contributed with materials/analyses, CLC, TN, SJ, KP, PR, HM, MH, DK, and MvdW were involved in analyses and interpretation of the data.",
            "startOffset": 46277,
            "title": "Authors' contribution"
        },
        {
            "endOffset": 36722,
            "parents": [
                {
                    "id": "s0035",
                    "title": "Results"
                },
                {
                    "id": "s0045",
                    "title": "Immunogenicity"
                }
            ],
            "secId": "s0055",
            "sentence": "Exploratory comparisons showed comparable rSBA GMTs for MenA and MenC between the Co-ad and PCV13/ACWY groups, whereas higher MenW and MenY GMTs were observed in the PCV13/ACWY group than in the Co-ad group (data not shown).",
            "startOffset": 36498,
            "title": "Co-administration of MenACWY-TT and PCV13"
        },
        {
            "endOffset": 38014,
            "parents": [
                {
                    "id": "s0035",
                    "title": "Results"
                }
            ],
            "secId": "s0060",
            "sentence": "The most frequent solicited general symptom was irritability/fussiness, reported in 44.7%, 47.7%, 54.3% and 43.4% of toddlers in the ACWY_1, ACWY_2, Co-ad and PCV13 groups, respectively, post-dose 1, and 40.2% and 35.1% of toddlers in the ACWY_2 and PCV13 groups, respectively, post-dose 2.",
            "startOffset": 37724,
            "title": "Safety"
        },
        {
            "endOffset": 43506,
            "parents": [],
            "refoffsets": {
                "b0070": {
                    "endOffset": 43505,
                    "startOffset": 43498
                },
                "b0170": {
                    "endOffset": 43505,
                    "startOffset": 43498
                }
            },
            "secId": "s0065",
            "sentence": "However, an enhancement of the immune response, especially for MenC and MenY, was observed for co-administration of MenACWY-TT with other TT-conjugate vaccines, potentially attributed to the higher quantity of TT [14,34].",
            "startOffset": 43285,
            "title": "Discussion"
        },
        {
            "endOffset": 31815,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methods"
                }
            ],
            "secId": "s0025",
            "sentence": "The occurrence of new onset of chronic illnesses and serious AEs (SAEs) were reported during the entire extended safety follow-up.",
            "startOffset": 31685,
            "title": "Assessments"
        },
        {
            "endOffset": 39488,
            "parents": [
                {
                    "id": "s0035",
                    "title": "Results"
                }
            ],
            "secId": "s0060",
            "sentence": "Two fatal SAEs were reported: 1 toddler in the Co-ad group died due to asphyxiation (121 days post-vaccination) and another in the PCV13/ACWY group due to aspiration of food (26 days post-vaccination with PCV13).",
            "startOffset": 39276,
            "title": "Safety"
        },
        {
            "endOffset": 27417,
            "parents": [],
            "secId": "s0005",
            "sentence": "This study investigates the short-term (at 1 month post-vaccination) and long-term (at 1, 3, and 5 years post-vaccination) immune responses induced by 1 or 2 doses of MenACWY-TT in toddlers.",
            "startOffset": 27227,
            "title": "Introduction"
        },
        {
            "endOffset": 36044,
            "parents": [
                {
                    "id": "s0035",
                    "title": "Results"
                },
                {
                    "id": "s0045",
                    "title": "Immunogenicity"
                }
            ],
            "secId": "s0055",
            "sentence": "Therefore, non-inferiority of the immune response to MenACWY-TT when co-administered with PCV13 versus MenACWY-TT given alone was demonstrated.",
            "startOffset": 35901,
            "title": "Co-administration of MenACWY-TT and PCV13"
        },
        {
            "endOffset": 39730,
            "parents": [
                {
                    "id": "s0035",
                    "title": "Results"
                }
            ],
            "secId": "s0060",
            "sentence": "Up to M9, new onset of chronic illnesses were reported in 4 (2.0%), 6 (3.0%), 1 (0.5%) and 7 (3.5%) toddlers in the ACWY_1, ACWY_2, Co-ad and PCV13/ACWY groups, respectively.",
            "startOffset": 39556,
            "title": "Safety"
        },
        {
            "endOffset": 32482,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methods"
                }
            ],
            "secId": "s0030",
            "sentence": "Immune responses for some vaccine antigens were evaluated in subsets of participants (Table S1).",
            "startOffset": 32386,
            "title": "Statistical analyses"
        },
        {
            "endOffset": 35593,
            "parents": [
                {
                    "id": "s0035",
                    "title": "Results"
                },
                {
                    "id": "s0045",
                    "title": "Immunogenicity"
                }
            ],
            "secId": "s0050",
            "sentence": "Percentages of toddlers with rSBA titres \u22651:128 and hSBA titres \u22651:8 for each serogroup are presented in Table S3.",
            "startOffset": 35479,
            "title": "Immunogenicity of 1 or 2 doses of MenACWY-TT"
        },
        {
            "endOffset": 26346,
            "parents": [],
            "refoffsets": {
                "b0010": {
                    "endOffset": 26345,
                    "startOffset": 26340
                },
                "b0040": {
                    "endOffset": 26345,
                    "startOffset": 26340
                }
            },
            "secId": "s0005",
            "sentence": "Meningococcal infections can be prevented through vaccination [2,8].",
            "startOffset": 26278,
            "title": "Introduction"
        },
        {
            "endOffset": 31496,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methods"
                }
            ],
            "refoffsets": {
                "b0115": {
                    "endOffset": 31435,
                    "startOffset": 31425
                },
                "b0130": {
                    "endOffset": 31495,
                    "startOffset": 31488
                },
                "b0135": {
                    "endOffset": 31495,
                    "startOffset": 31488
                }
            },
            "secId": "s0025",
            "sentence": "Thresholds of rSBA titres \u22651:8 and hSBA titres \u22651:4 have been previously associated with seroprotection against MenC [23,26,27], and were applied to all 4 serogroups in this study [26,27].",
            "startOffset": 31308,
            "title": "Assessments"
        },
        {
            "endOffset": 35479,
            "parents": [
                {
                    "id": "s0035",
                    "title": "Results"
                },
                {
                    "id": "s0045",
                    "title": "Immunogenicity"
                }
            ],
            "secId": "s0050",
            "sentence": "In exploratory analyses, higher values were observed in the ACWY_2 group (at M3) than in the ACWY_1 group (at M1) for percentages of participants with rSBA/hSBA titres above the pre-specified cut-offs for MenW and MenY, and for GMTs for MenC, MenW (both rSBA and hSBA) and MenY (hSBA) (Table S2).",
            "startOffset": 35183,
            "title": "Immunogenicity of 1 or 2 doses of MenACWY-TT"
        },
        {
            "endOffset": 28639,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methods"
                }
            ],
            "secId": "s0015",
            "sentence": "Participants were healthy 12\u201314-month-olds at the time of first vaccination, with documented receipt of the full primary series of PCV13 and diphtheria, tetanus and pertussis-containing vaccines according to local recommendations at least 5 months prior to enrolment.",
            "startOffset": 28372,
            "title": "Study design and participants"
        },
        {
            "endOffset": 29525,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methods"
                }
            ],
            "refoffsets": {
                "b0110": {
                    "endOffset": 29524,
                    "startOffset": 29520
                }
            },
            "secId": "s0015",
            "sentence": "PCV13 composition was previously described [22].",
            "startOffset": 29477,
            "title": "Study design and participants"
        },
        {
            "endOffset": 36497,
            "parents": [
                {
                    "id": "s0035",
                    "title": "Results"
                },
                {
                    "id": "s0045",
                    "title": "Immunogenicity"
                }
            ],
            "secId": "s0055",
            "sentence": "One month post-vaccination with MenACWY-TT, percentages of toddlers with rSBA titres \u22651:8 ranged from 90.0% to 96.1% in the Co-ad group and from 95.3% to 97.1% in the PCV13/ACWY group (Table 2).",
            "startOffset": 36303,
            "title": "Co-administration of MenACWY-TT and PCV13"
        },
        {
            "endOffset": 26164,
            "parents": [],
            "refoffsets": {
                "b0015": {
                    "endOffset": 26163,
                    "startOffset": 26160
                }
            },
            "secId": "s0005",
            "sentence": "Their prevalence varies geographically, with MenB, MenC and MenY being more prominent in the Americas and Europe, MenA and MenC in Asia, and MenA, MenC and MenW in Africa [3].",
            "startOffset": 25989,
            "title": "Introduction"
        },
        {
            "endOffset": 35183,
            "parents": [
                {
                    "id": "s0035",
                    "title": "Results"
                },
                {
                    "id": "s0045",
                    "title": "Immunogenicity"
                }
            ],
            "secId": "s0050",
            "sentence": "Post-dose 2, percentages of toddlers with hSBA titres \u22651:4 in the ACWY_2 group were 97.0%, 100%, 97.1% and 95.3%, and hSBA GMTs increased 65.6-, 876.7-, 378.4- and 205.2-fold from pre-vaccination levels, for MenA, MenC, MenW and MenY, respectively (Table 3).",
            "startOffset": 34925,
            "title": "Immunogenicity of 1 or 2 doses of MenACWY-TT"
        },
        {
            "endOffset": 47857,
            "parents": [],
            "secId": "s0085",
            "sentence": "PR has been a member of scientific vaccine advisory boards for industry (Pfizer, GSK, Sanofi) but has not received any personal payments from industry.",
            "startOffset": 47706,
            "title": "Conflict of interest"
        },
        {
            "endOffset": 48087,
            "parents": [],
            "secId": "s0085",
            "sentence": "The other authors have no conflict of interest to disclose.",
            "startOffset": 48028,
            "title": "Conflict of interest"
        },
        {
            "endOffset": 33440,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methods"
                }
            ],
            "secId": "s0030",
            "sentence": "Details on computing GMTs/GMCs and other derived data are provided in Text S1.",
            "startOffset": 33362,
            "title": "Statistical analyses"
        },
        {
            "endOffset": 31078,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methods"
                }
            ],
            "secId": "s0025",
            "sentence": "Blood samples (\u223c5 mL) were collected from toddlers at pre-vaccination, and 1 month post-each vaccination.",
            "startOffset": 30973,
            "title": "Assessments"
        },
        {
            "endOffset": 40972,
            "parents": [],
            "refoffsets": {
                "b0145": {
                    "endOffset": 40881,
                    "startOffset": 40877
                }
            },
            "secId": "s0065",
            "sentence": "Although hSBA titres are believed to underestimate complement-mediated killing of some N. meningitidis strains [29], both assays are currently used to evaluate meningococcal vaccines for licensure purposes.",
            "startOffset": 40766,
            "title": "Discussion"
        },
        {
            "endOffset": 41347,
            "parents": [],
            "refoffsets": {
                "b0060": {
                    "endOffset": 41346,
                    "startOffset": 41342
                }
            },
            "secId": "s0065",
            "sentence": "This difference is not fully understood, but it was no longer observed in our study after administration of the second MenACWY-TT dose, similarly with previous reports [12].",
            "startOffset": 41174,
            "title": "Discussion"
        },
        {
            "endOffset": 45675,
            "parents": [],
            "secId": "s0070",
            "sentence": "The implementation of co-administered MenACWY-TT and PCV13 vaccinations in paediatric immunisation programmes could be warranted, as the reduced number of visits might lead to higher compliance and an improved uptake and coverage for both vaccines.",
            "startOffset": 45427,
            "title": "Conclusions"
        },
        {
            "endOffset": 46276,
            "parents": [],
            "secId": "s0080",
            "sentence": "Drafts were developed by a professional publication writer according to the recommendations, documentation, and outline provided by the lead author.",
            "startOffset": 46128,
            "title": "Authors' contribution"
        },
        {
            "endOffset": 30354,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methods"
                }
            ],
            "secId": "s0020",
            "sentence": "The immunogenicity of 1 or 2 doses of MenACWY-TT was compared at 1 month following last vaccination, in terms of serum bactericidal activity using rabbit complement (rSBA) titres.",
            "startOffset": 30175,
            "title": "Objectives"
        },
        {
            "endOffset": 42620,
            "parents": [],
            "secId": "s0065",
            "sentence": "Our study demonstrated the non-inferiority of the immune responses to MenACWY-TT and PCV13 when co-administered versus their separate administration in toddlers.",
            "startOffset": 42459,
            "title": "Discussion"
        },
        {
            "endOffset": 42817,
            "parents": [],
            "refoffsets": {
                "b0070": {
                    "endOffset": 42752,
                    "startOffset": 42745
                },
                "b0080": {
                    "endOffset": 42752,
                    "startOffset": 42745
                },
                "b0160": {
                    "endOffset": 42789,
                    "startOffset": 42785
                }
            },
            "secId": "s0065",
            "sentence": "This is in line with previous studies showing that MenACWY-TT can be co-administered with other routine paediatric vaccines [14,16] or with 10-valent PCV (PHiD-CV) [32] in the second year of life.",
            "startOffset": 42621,
            "title": "Discussion"
        },
        {
            "endOffset": 46127,
            "parents": [],
            "secId": "s0080",
            "sentence": "All authors had full access to the data and had final responsibility to submit for publication.",
            "startOffset": 46032,
            "title": "Authors' contribution"
        },
        {
            "endOffset": 34646,
            "parents": [
                {
                    "id": "s0035",
                    "title": "Results"
                },
                {
                    "id": "s0045",
                    "title": "Immunogenicity"
                }
            ],
            "secId": "s0050",
            "sentence": "One month post-dose 2, 98.0%, 98.7%, 100% and 99.3% of toddlers in the ACWY_2 group had rSBA titres \u22651:8 and rSBA GMTs increased 250.3-, 152.2-, 803.0-, and 218.0-fold from pre-vaccination levels for MenA, MenC, MenW and MenY, respectively (Table 2).",
            "startOffset": 34396,
            "title": "Immunogenicity of 1 or 2 doses of MenACWY-TT"
        },
        {
            "endOffset": 48148,
            "parents": [],
            "secId": "s0090",
            "sentence": "Menactra is a trademark of Sanofi Pasteur.",
            "startOffset": 48106,
            "title": "Trademark statement"
        },
        {
            "endOffset": 47502,
            "parents": [],
            "secId": "s0085",
            "sentence": "Her institution has received funding for investigator led research from GSK, Pfizer and Seqirus.",
            "startOffset": 47406,
            "title": "Conflict of interest"
        },
        {
            "endOffset": 30162,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methods"
                }
            ],
            "secId": "s0015",
            "sentence": "The study is registered at www.clinicaltrials.gov (NCT01939158) and a protocol summary is available at https://www.gsk-clinicalstudyregister.com (116892).",
            "startOffset": 30008,
            "title": "Study design and participants"
        },
        {
            "endOffset": 40076,
            "parents": [],
            "secId": "s0065",
            "sentence": "rSBA GMTs and, to a lesser extent, hSBA GMTs increased markedly compared with pre-vaccination levels.",
            "startOffset": 39975,
            "title": "Discussion"
        },
        {
            "endOffset": 40593,
            "parents": [],
            "refoffsets": {
                "b0060": {
                    "endOffset": 40592,
                    "startOffset": 40585
                },
                "b0105": {
                    "endOffset": 40592,
                    "startOffset": 40585
                }
            },
            "secId": "s0065",
            "sentence": "After 1 dose of MenACWY-TT, immune responses as measured by rSBA were higher than those assessed by hSBA, in line with previous observations in toddlers [12,21].",
            "startOffset": 40432,
            "title": "Discussion"
        },
        {
            "endOffset": 25876,
            "parents": [],
            "refoffsets": {
                "b0005": {
                    "endOffset": 25875,
                    "startOffset": 25870
                },
                "b0010": {
                    "endOffset": 25875,
                    "startOffset": 25870
                }
            },
            "secId": "s0005",
            "sentence": "Invasive meningococcal disease and meningococcal meningitis caused by Neisseria meningitidis have their highest incidence in infants, with a second peak in adolescents and young adults [1,2].",
            "startOffset": 25685,
            "title": "Introduction"
        },
        {
            "endOffset": 29143,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methods"
                }
            ],
            "secId": "s0015",
            "sentence": "Randomisation was performed using a web-based system, with a minimisation algorithm accounting for centre, country and number of PCV13 doses (2 or 3, received before study start) with equal weight.",
            "startOffset": 28946,
            "title": "Study design and participants"
        },
        {
            "endOffset": 39790,
            "parents": [
                {
                    "id": "s0035",
                    "title": "Results"
                }
            ],
            "secId": "s0060",
            "sentence": "Eczema and asthma were the most commonly reported symptoms.",
            "startOffset": 39731,
            "title": "Safety"
        },
        {
            "endOffset": 44638,
            "parents": [],
            "secId": "s0065",
            "sentence": "Study limitations include the fact that the 2-dose schedule of MenACWY-TT co-administered with PCV13 was not assessed.",
            "startOffset": 44520,
            "title": "Discussion"
        },
        {
            "endOffset": 42997,
            "parents": [],
            "refoffsets": {
                "b0160": {
                    "endOffset": 42962,
                    "startOffset": 42958
                }
            },
            "secId": "s0065",
            "sentence": "While lower responses to serotype 18C were previously observed when MenACWY-TT was co-administered with PHiD-CV compared with PHiD-CV alone [32], this was not observed with PCV13.",
            "startOffset": 42818,
            "title": "Discussion"
        },
        {
            "endOffset": 39004,
            "parents": [
                {
                    "id": "s0035",
                    "title": "Results"
                }
            ],
            "secId": "s0060",
            "sentence": "Up to M9, 10 (4.9%) toddlers in the ACWY_1 group, 10 (5.1%) in the ACWY_2 group, 11 (5.5%) in the Co-ad group, and 15 (7.5%) in the PCV13/ACWY group experienced \u22651 SAE.",
            "startOffset": 38836,
            "title": "Safety"
        },
        {
            "endOffset": 47298,
            "parents": [],
            "secId": "s0085",
            "sentence": "KP\u2019s institution, Murdoch Childrens Research Institute (MCRI), has received research grants from GSK, Novartis, Pfizer, Novavax, and MedImmune during the conduct of the study.",
            "startOffset": 47123,
            "title": "Conflict of interest"
        },
        {
            "endOffset": 28310,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methods"
                }
            ],
            "secId": "s0015",
            "sentence": "The study interventions were performed in the vaccination phase (October 2013 to February 2015) lasting up to 3 months from first vaccination.",
            "startOffset": 28168,
            "title": "Study design and participants"
        },
        {
            "endOffset": 29339,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methods"
                }
            ],
            "secId": "s0015",
            "sentence": "The open-label design was imposed by differences in the vaccines\u2019 appearance and vaccination schedules for each group, but the personnel in charge of laboratory testing were blinded to treatment.",
            "startOffset": 29144,
            "title": "Study design and participants"
        },
        {
            "endOffset": 32042,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methods"
                }
            ],
            "secId": "s0030",
            "sentence": "Eight hundred toddlers were planned to be enrolled (200 per group) to achieve a sample size of 160 evaluable children in each group.",
            "startOffset": 31910,
            "title": "Statistical analyses"
        },
        {
            "endOffset": 30007,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methods"
                }
            ],
            "secId": "s0015",
            "sentence": "The study protocol, amendments and informed consent forms were approved by independent ethics committees at each site.",
            "startOffset": 29889,
            "title": "Study design and participants"
        },
        {
            "endOffset": 39974,
            "parents": [],
            "secId": "s0065",
            "sentence": "After 1 dose, \u226592.8% of toddlers had rSBA titres \u22651:8 for each meningococcal serogroup.",
            "startOffset": 39887,
            "title": "Discussion"
        },
        {
            "endOffset": 29782,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methods"
                }
            ],
            "secId": "s0015",
            "sentence": "The study was conducted in agreement with the Declaration of Helsinki and the principles of Good Clinical Practice.",
            "startOffset": 29667,
            "title": "Study design and participants"
        },
        {
            "endOffset": 46011,
            "parents": [],
            "secId": "s0075",
            "sentence": "GlaxoSmithKline Biologicals SA also took in charge all costs associated to the development and publishing of the present manuscript.",
            "startOffset": 45879,
            "title": "Funding"
        },
        {
            "endOffset": 27560,
            "parents": [],
            "secId": "s0005",
            "sentence": "The study long-term follow-up is ongoing; here, we report the short-term immunogenicity and safety data up to 9 months post-first vaccination.",
            "startOffset": 27418,
            "title": "Introduction"
        },
        {
            "endOffset": 37661,
            "parents": [
                {
                    "id": "s0035",
                    "title": "Results"
                }
            ],
            "secId": "s0060",
            "sentence": "Redness was also the most frequent symptom following PCV13 vaccination, reported in 44.4% of toddlers in the Co-ad group and 45.9% in the PCV13/ACWY group.",
            "startOffset": 37506,
            "title": "Safety"
        },
        {
            "endOffset": 48276,
            "parents": [],
            "secId": "s0090",
            "sentence": "Nimenrix is a trademark of the GSK group of companies, licensed to Pfizer.",
            "startOffset": 48202,
            "title": "Trademark statement"
        },
        {
            "endOffset": 29667,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methods"
                }
            ],
            "secId": "s0015",
            "sentence": "At each vaccination, a 0.5 mL dose was administered intramuscularly in the left (MenACWY-TT) or right (PCV13) anterolateral thigh or deltoid.",
            "startOffset": 29526,
            "title": "Study design and participants"
        },
        {
            "endOffset": 45153,
            "parents": [],
            "secId": "s0070",
            "sentence": "Vaccination with either 1 or 2 doses of MenACWY-TT in toddlers elicited robust short-term immune responses to all serogroups, with substantial increases in GMTs from pre-vaccination levels after each vaccination.",
            "startOffset": 44941,
            "title": "Conclusions"
        },
        {
            "endOffset": 35900,
            "parents": [
                {
                    "id": "s0035",
                    "title": "Results"
                },
                {
                    "id": "s0045",
                    "title": "Immunogenicity"
                }
            ],
            "secId": "s0055",
            "sentence": "One month post-dose 1, the LLs of the 95% CIs for the differences between the Co-ad and pooled ACWY_1 and ACWY_2 groups in percentages of toddlers with post-vaccination rSBA titres \u22651:8 ranged between \u22129.16 and \u22123.59 for all meningococcal serogroups (Table S4).",
            "startOffset": 35639,
            "title": "Co-administration of MenACWY-TT and PCV13"
        },
        {
            "endOffset": 34924,
            "parents": [
                {
                    "id": "s0035",
                    "title": "Results"
                },
                {
                    "id": "s0045",
                    "title": "Immunogenicity"
                }
            ],
            "secId": "s0050",
            "sentence": "One month post-dose 1, percentages of toddlers with hSBA titres \u22651:4 in the ACWY_1 and ACWY_2 groups were \u226596.0% for MenA, \u226595.7% for MenC, \u226562.5% for MenW and \u226564.3% for MenY, with GMTs increasing \u226549.2-, \u226569.0-, \u226512.5- and \u226512.8-fold from pre-vaccination levels, respectively.",
            "startOffset": 34646,
            "title": "Immunogenicity of 1 or 2 doses of MenACWY-TT"
        },
        {
            "endOffset": 36189,
            "parents": [
                {
                    "id": "s0035",
                    "title": "Results"
                },
                {
                    "id": "s0045",
                    "title": "Immunogenicity"
                }
            ],
            "secId": "s0055",
            "sentence": "For each PCV13 serotype, the LLs of the 95% CIs for the GMC ratios between the Co-ad and the PCV13 group ranged between 0.87 and 1.03 (Table S5).",
            "startOffset": 36044,
            "title": "Co-administration of MenACWY-TT and PCV13"
        },
        {
            "endOffset": 45426,
            "parents": [],
            "secId": "s0070",
            "sentence": "MenACWY-TT and PCV13 can be co-administered without impairing the immunogenicity or safety profile of either vaccine.",
            "startOffset": 45309,
            "title": "Conclusions"
        },
        {
            "endOffset": 33361,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methods"
                }
            ],
            "secId": "s0030",
            "sentence": "Immune responses in the ACWY_2 group (at M3) and the ACWY_1 group (at M1) were compared in exploratory analyses (Text S1).",
            "startOffset": 33239,
            "title": "Statistical analyses"
        },
        {
            "endOffset": 37724,
            "parents": [
                {
                    "id": "s0035",
                    "title": "Results"
                }
            ],
            "secId": "s0060",
            "sentence": "Grade 3 symptoms were reported in \u22645.1% of toddlers (Fig. 2A).",
            "startOffset": 37662,
            "title": "Safety"
        },
        {
            "endOffset": 41897,
            "parents": [],
            "secId": "s0065",
            "sentence": "This suggests that a 2-dose regimen may substantially improve short-term immune responses to these serogroups.",
            "startOffset": 41787,
            "title": "Discussion"
        },
        {
            "endOffset": 43284,
            "parents": [],
            "refoffsets": {
                "b0165": {
                    "endOffset": 43283,
                    "startOffset": 43279
                }
            },
            "secId": "s0065",
            "sentence": "A potential explanation for this difference could be the reduced polysaccharide responses induced by multivalent conjugate vaccines using TT as carrier protein compared with CRM197 since the capsular polysaccharide of serotype 18 is conjugated to TT in PHiD-CV and CRM197 in PCV13 [33].",
            "startOffset": 42998,
            "title": "Discussion"
        },
        {
            "endOffset": 27020,
            "parents": [],
            "refoffsets": {
                "b0055": {
                    "endOffset": 26896,
                    "startOffset": 26892
                },
                "b0060": {
                    "endOffset": 26927,
                    "startOffset": 26920
                },
                "b0065": {
                    "endOffset": 26927,
                    "startOffset": 26920
                },
                "b0070": {
                    "endOffset": 26927,
                    "startOffset": 26920
                },
                "b0075": {
                    "endOffset": 26927,
                    "startOffset": 26920
                },
                "b0080": {
                    "endOffset": 26927,
                    "startOffset": 26920
                },
                "b0085": {
                    "endOffset": 27019,
                    "startOffset": 27012
                },
                "b0090": {
                    "endOffset": 27019,
                    "startOffset": 27012
                },
                "b0095": {
                    "endOffset": 27019,
                    "startOffset": 27012
                },
                "b0100": {
                    "endOffset": 27019,
                    "startOffset": 27012
                },
                "b0105": {
                    "endOffset": 27019,
                    "startOffset": 27012
                }
            },
            "secId": "s0005",
            "sentence": "Previous studies have shown that a single dose of MenACWY-TT is immunogenic with a clinically acceptable safety profile in infants [11], toddlers and children [12\u201316], and persistence of the immune response was observed up to 5 years post-vaccination [17\u201321].",
            "startOffset": 26761,
            "title": "Introduction"
        },
        {
            "endOffset": 40765,
            "parents": [],
            "refoffsets": {
                "b0140": {
                    "endOffset": 40764,
                    "startOffset": 40760
                }
            },
            "secId": "s0065",
            "sentence": "A recent study comparing MenACWY-TT and MenACWY-CRM in 12\u201315-month-olds also found more prominent rSBA than hSBA responses following administration of either vaccine [28].",
            "startOffset": 40594,
            "title": "Discussion"
        },
        {
            "endOffset": 44428,
            "parents": [],
            "secId": "s0065",
            "sentence": "Non-inferiority endpoints were assessed with sufficient power.",
            "startOffset": 44366,
            "title": "Discussion"
        },
        {
            "endOffset": 47122,
            "parents": [],
            "secId": "s0085",
            "sentence": "TN reports grants from GSK during the conduct of the study.",
            "startOffset": 47063,
            "title": "Conflict of interest"
        },
        {
            "endOffset": 33239,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methods"
                }
            ],
            "secId": "s0030",
            "sentence": "Co-administration of PCV13 and MenACWY-TT was considered non-inferior to administration of PCV13 alone if the LL of the 95% CI for the geometric mean concentration (GMC) ratio between the Co-ad group and the PCV13 group was \u22650.5 for each vaccine serotype.",
            "startOffset": 32984,
            "title": "Statistical analyses"
        },
        {
            "endOffset": 32983,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methods"
                }
            ],
            "secId": "s0030",
            "sentence": "Co-administration of MenACWY-TT and PCV13 was considered non-inferior to administration of MenACWY-TT alone if the lower limit (LL) of the 2-sided 95% confidence interval (CI) for the difference between the Co-ad group and the ACWY_pooled group (pooled ACWY_1 and ACWY_2 data) in the percentage of toddlers with rSBA titres \u22651:8 at M1 was \u2265\u221210% for each meningococcal serogroup.",
            "startOffset": 32605,
            "title": "Statistical analyses"
        },
        {
            "endOffset": 44251,
            "parents": [],
            "secId": "s0065",
            "sentence": "No increase in the incidence of AEs was observed after the administration of a second MenACWY-TT dose, which supports the tolerability of a 2-dose schedule in toddlers.",
            "startOffset": 44083,
            "title": "Discussion"
        },
        {
            "endOffset": 47062,
            "parents": [],
            "secId": "s0085",
            "sentence": "PR reports grants from GSK during the conduct of the study and participated in scientific advisory board for GSK for novel pneumococcal vaccine with no personal honorarium.",
            "startOffset": 46890,
            "title": "Conflict of interest"
        },
        {
            "endOffset": 44519,
            "parents": [],
            "secId": "s0065",
            "sentence": "Meningococcal antibody persistence will continue to be evaluated at subsequent timepoints.",
            "startOffset": 44429,
            "title": "Discussion"
        },
        {
            "endOffset": 30477,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methods"
                }
            ],
            "secId": "s0020",
            "sentence": "Evaluation of the persistence of the immune response at years 1, 3 and 5 is still ongoing (exploratory primary objective).",
            "startOffset": 30355,
            "title": "Objectives"
        },
        {
            "endOffset": 41581,
            "parents": [],
            "refoffsets": {
                "b0060": {
                    "endOffset": 41580,
                    "startOffset": 41576
                }
            },
            "secId": "s0065",
            "sentence": "Moreover, robust increases in GMTs from pre-vaccination levels were noted, in line with previous observations in toddlers [12].",
            "startOffset": 41454,
            "title": "Discussion"
        },
        {
            "endOffset": 41173,
            "parents": [],
            "refoffsets": {
                "b0055": {
                    "endOffset": 41137,
                    "startOffset": 41133
                },
                "b0060": {
                    "endOffset": 41120,
                    "startOffset": 41113
                },
                "b0105": {
                    "endOffset": 41120,
                    "startOffset": 41113
                },
                "b0150": {
                    "endOffset": 41172,
                    "startOffset": 41165
                },
                "b0155": {
                    "endOffset": 41172,
                    "startOffset": 41165
                }
            },
            "secId": "s0065",
            "sentence": "Higher hSBA responses to MenA and MenC than to MenY and MenW have been previously reported following vaccination with MenACWY-TT in toddlers [12,21] and infants [11] or MenACWY-CRM in toddlers [30,31].",
            "startOffset": 40972,
            "title": "Discussion"
        },
        {
            "endOffset": 46889,
            "parents": [],
            "secId": "s0085",
            "sentence": "CLC reports grants from GSK during the conduct of the study and grants outside the submitted work, and is an investigator on vaccine trials sponsored by industry including GSK, Sanofi, Novartis, Novavax, MedImmune and Pfizer during the conduct of the study.",
            "startOffset": 46632,
            "title": "Conflict of interest"
        },
        {
            "endOffset": 30591,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methods"
                }
            ],
            "secId": "s0020",
            "sentence": "The same comparisons were performed in terms of serum bactericidal activity using human complement (hSBA) titres.",
            "startOffset": 30478,
            "title": "Objectives"
        },
        {
            "endOffset": 47966,
            "parents": [],
            "secId": "s0085",
            "sentence": "MvdW is an employee of the GSK group of companies.",
            "startOffset": 47916,
            "title": "Conflict of interest"
        },
        {
            "endOffset": 27227,
            "parents": [],
            "refoffsets": {
                "b0060": {
                    "endOffset": 27226,
                    "startOffset": 27222
                }
            },
            "secId": "s0005",
            "sentence": "However, data suggest that protection against MenW and MenY in toddlers who received their first dose of MenACWY-TT at 9 months might be improved by administration of a second dose at 12 months of age [12].",
            "startOffset": 27021,
            "title": "Introduction"
        },
        {
            "endOffset": 42085,
            "parents": [],
            "refoffsets": {
                "b0060": {
                    "endOffset": 42084,
                    "startOffset": 42080
                }
            },
            "secId": "s0065",
            "sentence": "Higher percentages of toddlers with MenC, MenW and MenY hSBA titres \u22651:4 and higher hSBA GMTs were previously reported following vaccination with 2 doses versus 1 dose of MenACWY-TT [12].",
            "startOffset": 41898,
            "title": "Discussion"
        },
        {
            "endOffset": 38667,
            "parents": [
                {
                    "id": "s0035",
                    "title": "Results"
                }
            ],
            "secId": "s0060",
            "sentence": "Following second vaccination, \u22651 unsolicited AE was reported in 34.5% and 30.3% and \u22651 grade 3 unsolicited AE in 7.1% and 5.5% of toddlers in the ACWY_2 and PCV13/ACWY groups, respectively.",
            "startOffset": 38478,
            "title": "Safety"
        },
        {
            "endOffset": 39886,
            "parents": [],
            "secId": "s0065",
            "sentence": "This study demonstrated that 1 or 2 doses of MenACWY-TT were immunogenic in toddlers.",
            "startOffset": 39801,
            "title": "Discussion"
        },
        {
            "endOffset": 42459,
            "parents": [],
            "secId": "s0065",
            "sentence": "Our study is still ongoing to evaluate the persistence of responses to 1 or 2 doses of MenACWY-TT beyond 1 year post-vaccination.",
            "startOffset": 42330,
            "title": "Discussion"
        },
        {
            "endOffset": 44365,
            "parents": [],
            "secId": "s0065",
            "sentence": "The main strength of this study is that it allows the comparison of 1- and 2-dose MenACWY-TT regimens in toddlers.",
            "startOffset": 44251,
            "title": "Discussion"
        },
        {
            "endOffset": 38836,
            "parents": [
                {
                    "id": "s0035",
                    "title": "Results"
                }
            ],
            "secId": "s0060",
            "sentence": "Vaccine-related AEs were reported in 4.6% and 2.5% of participants in the ACWY_2 and PCV13/ACWY groups, respectively, with diarrhoea and vomiting being the most common.",
            "startOffset": 38668,
            "title": "Safety"
        },
        {
            "endOffset": 47915,
            "parents": [],
            "secId": "s0085",
            "sentence": "DK and MH were employees of GSK at the time of the study.",
            "startOffset": 47858,
            "title": "Conflict of interest"
        },
        {
            "endOffset": 41786,
            "parents": [],
            "secId": "s0065",
            "sentence": "Exploratory analyses showed that for MenW and MenY, percentages of toddlers with rSBA and hSBA titres indicative of protection and hSBA GMTs were higher following 2 doses compared to 1 dose of MenACWY-TT.",
            "startOffset": 41582,
            "title": "Discussion"
        },
        {
            "endOffset": 43922,
            "parents": [],
            "secId": "s0065",
            "sentence": "Therefore, the safety profiles of either vaccine was not impacted by co-administration.",
            "startOffset": 43835,
            "title": "Discussion"
        },
        {
            "endOffset": 26640,
            "parents": [],
            "secId": "s0005",
            "sentence": "Three quadrivalent meningococcal conjugate vaccines are currently available, using (i) diphtheria toxoid (Menactra, Sanofi Pasteur), (ii) non-toxic diphtheria cross-reacting mutant CRM197 (MenACWY-CRM197; Menveo, GSK) or (iii) tetanus toxoid (MenACWY-TT; Nimenrix, Pfizer) as carrier proteins.",
            "startOffset": 26347,
            "title": "Introduction"
        },
        {
            "endOffset": 33910,
            "parents": [
                {
                    "id": "s0035",
                    "title": "Results"
                }
            ],
            "secId": "s0040",
            "sentence": "A total of 804 toddlers were enrolled and 802 (167 in Australia, 137 in Canada, 206 in the Czech Republic, 29 in Panama, 204 in South Africa and 59 in Turkey) were included in the total vaccinated cohort (Fig. 1).",
            "startOffset": 33697,
            "title": "Demographics"
        },
        {
            "endOffset": 39556,
            "parents": [
                {
                    "id": "s0035",
                    "title": "Results"
                }
            ],
            "secId": "s0060",
            "sentence": "Neither death was considered to be causally related to vaccination.",
            "startOffset": 39489,
            "title": "Safety"
        },
        {
            "endOffset": 40432,
            "parents": [],
            "secId": "s0065",
            "sentence": "Co-administration of MenACWY-TT and PCV13 in toddlers did not impact the immunogenicity or safety profile of either vaccine.",
            "startOffset": 40308,
            "title": "Discussion"
        },
        {
            "endOffset": 43834,
            "parents": [],
            "refoffsets": {
                "b0050": {
                    "endOffset": 43833,
                    "startOffset": 43826
                },
                "b0175": {
                    "endOffset": 43833,
                    "startOffset": 43826
                }
            },
            "secId": "s0065",
            "sentence": "The overall incidence of AEs following co-administration of MenACWY-TT with PCV13 was comparable to that following separate administration, as observed in this and previous studies [10,35].",
            "startOffset": 43645,
            "title": "Discussion"
        },
        {
            "endOffset": 32385,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methods"
                }
            ],
            "secId": "s0030",
            "sentence": "Immunogenicity analyses were performed on the according-to-protocol cohorts at each timepoint, which included all evaluable vaccinated toddlers for whom immunogenicity results were available.",
            "startOffset": 32194,
            "title": "Statistical analyses"
        },
        {
            "endOffset": 34395,
            "parents": [
                {
                    "id": "s0035",
                    "title": "Results"
                },
                {
                    "id": "s0045",
                    "title": "Immunogenicity"
                }
            ],
            "secId": "s0050",
            "sentence": "In both groups, rSBA GMTs increased \u2265271.3-, \u226587.9-, \u2265461.4-, and \u2265179.5-fold from pre-vaccination levels for MenA, MenC, MenW and MenY respectively.",
            "startOffset": 34246,
            "title": "Immunogenicity of 1 or 2 doses of MenACWY-TT"
        },
        {
            "endOffset": 47600,
            "parents": [],
            "secId": "s0085",
            "sentence": "PR is an investigator on vaccine trials sponsored by industry including GSK, Novartis and Pfizer.",
            "startOffset": 47503,
            "title": "Conflict of interest"
        },
        {
            "endOffset": 29888,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methods"
                }
            ],
            "secId": "s0015",
            "sentence": "Written informed consent was obtained from parents/legally acceptable representatives prior to enrolment.",
            "startOffset": 29783,
            "title": "Study design and participants"
        },
        {
            "endOffset": 30840,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methods"
                }
            ],
            "secId": "s0020",
            "sentence": "The non-inferiority of co-administration of MenACWY-TT and PCV13 versus administration of either MenACWY-TT or PCV13 alone was evaluated at 1 month following last vaccination with MenACWY-TT and PCV13, respectively (confirmatory primary objectives).",
            "startOffset": 30591,
            "title": "Objectives"
        },
        {
            "endOffset": 28167,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methods"
                }
            ],
            "secId": "s0015",
            "sentence": "This phase III, randomised, open-label, controlled, multicentre study was conducted in Australia, Canada, Czech Republic, Panama, South Africa and Turkey.",
            "startOffset": 28013,
            "title": "Study design and participants"
        },
        {
            "endOffset": 34003,
            "parents": [
                {
                    "id": "s0035",
                    "title": "Results"
                }
            ],
            "secId": "s0040",
            "sentence": "The groups were well-balanced in terms of age, gender and geographic distribution (Table 1).",
            "startOffset": 33911,
            "title": "Demographics"
        },
        {
            "endOffset": 47405,
            "parents": [],
            "secId": "s0085",
            "sentence": "HM is an investigator on clinical vaccine studies sponsored by industry including GSK, Pfizer and Novavax.",
            "startOffset": 47299,
            "title": "Conflict of interest"
        },
        {
            "endOffset": 48201,
            "parents": [],
            "secId": "s0090",
            "sentence": "Menveo is a trademark of the GSK group of companies.",
            "startOffset": 48149,
            "title": "Trademark statement"
        },
        {
            "endOffset": 38144,
            "parents": [
                {
                    "id": "s0035",
                    "title": "Results"
                }
            ],
            "secId": "s0060",
            "sentence": "General symptoms had comparable incidences among the 4 groups, and grade 3 symptoms were reported in \u22646.6% of toddlers (Fig. 2B).",
            "startOffset": 38015,
            "title": "Safety"
        },
        {
            "endOffset": 40307,
            "parents": [],
            "secId": "s0065",
            "sentence": "A second dose administered after 2 months elicited comparable rSBA and hSBA immune responses, with the vast majority of toddlers having titres indicative of protection and substantial increases in GMTs from pre-vaccination levels.",
            "startOffset": 40077,
            "title": "Discussion"
        },
        {
            "endOffset": 38280,
            "parents": [
                {
                    "id": "s0035",
                    "title": "Results"
                }
            ],
            "secId": "s0060",
            "sentence": "Following first vaccination, \u22651 unsolicited AE was reported in 42.3\u201346.2% and \u22651 grade 3 AE in 7.4\u20138.0% of participants in the 4 groups.",
            "startOffset": 38144,
            "title": "Safety"
        },
        {
            "endOffset": 39275,
            "parents": [
                {
                    "id": "s0035",
                    "title": "Results"
                }
            ],
            "secId": "s0060",
            "sentence": "Four SAEs were considered related to vaccination: leukopenia and neutropenia (2 days post-dose 1) and pneumonia (169 days post-dose 2) for 2 toddlers in the ACWY_2 group, and pneumonia (45 days post-vaccination) for a toddler in the Co-ad group; all were resolved by M9.",
            "startOffset": 39005,
            "title": "Safety"
        },
        {
            "endOffset": 29476,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methods"
                }
            ],
            "secId": "s0015",
            "sentence": "One 0.5 mL-dose of MenACWY-TT contained 5 \u03bcg of each MenA, MenC, MenW and MenY polysaccharide conjugated to TT (total TT content \u223c44 \u03bcg).",
            "startOffset": 29339,
            "title": "Study design and participants"
        },
        {
            "endOffset": 37251,
            "parents": [
                {
                    "id": "s0035",
                    "title": "Results"
                },
                {
                    "id": "s0045",
                    "title": "Immunogenicity"
                }
            ],
            "secId": "s0055",
            "sentence": "Percentages of toddlers with opsonophagocytic activity assay titres \u22651:8 ranged from 90.7% to 100% in both groups (Table 4).",
            "startOffset": 37127,
            "title": "Co-administration of MenACWY-TT and PCV13"
        },
        {
            "endOffset": 33557,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methods"
                }
            ],
            "secId": "s0030",
            "sentence": "Safety analyses were conducted on the total vaccinated cohort, including toddlers who received \u22651 study vaccine dose.",
            "startOffset": 33440,
            "title": "Statistical analyses"
        },
        {
            "endOffset": 31887,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methods"
                }
            ],
            "secId": "s0025",
            "sentence": "Vaccine-related SAEs will continue to be recorded throughout the study.",
            "startOffset": 31816,
            "title": "Assessments"
        },
        {
            "endOffset": 32604,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methods"
                }
            ],
            "secId": "s0030",
            "sentence": "The confirmatory objectives were assessed hierarchically: the first objective had to be met to demonstrate the second one.",
            "startOffset": 32482,
            "title": "Statistical analyses"
        },
        {
            "endOffset": 27973,
            "parents": [],
            "secId": "s0005",
            "sentence": "Since the recommended timing of vaccination could coincide with the administration of a booster dose of pneumococcal conjugate vaccine (PCV), according to paediatric immunisation programmes worldwide, we also aimed to determine whether co-administration of MenACWY-TT with the booster dose of the 13-valent PCV (PCV13; Prevnar/Prevenar 13, Pfizer) impacted the immunogenicity or safety of either of the vaccines.",
            "startOffset": 27561,
            "title": "Introduction"
        },
        {
            "endOffset": 37126,
            "parents": [
                {
                    "id": "s0035",
                    "title": "Results"
                },
                {
                    "id": "s0045",
                    "title": "Immunogenicity"
                }
            ],
            "secId": "s0055",
            "sentence": "For each PCV13 serotype, except serotype 3, \u226599.4% and \u226598.3% of toddlers had antibody concentrations \u22650.15 and \u22650.26 \u03bcg/ml, respectively (Table S6).",
            "startOffset": 36977,
            "title": "Co-administration of MenACWY-TT and PCV13"
        },
        {
            "endOffset": 28372,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methods"
                }
            ],
            "secId": "s0015",
            "sentence": "A 6 M extended safety follow-up was completed in August 2015.",
            "startOffset": 28311,
            "title": "Study design and participants"
        },
        {
            "endOffset": 36303,
            "parents": [
                {
                    "id": "s0035",
                    "title": "Results"
                },
                {
                    "id": "s0045",
                    "title": "Immunogenicity"
                }
            ],
            "secId": "s0055",
            "sentence": "Thus, immune response to PCV13 when co-administered with MenACWY-TT was non-inferior to PCV13 administered alone.",
            "startOffset": 36190,
            "title": "Co-administration of MenACWY-TT and PCV13"
        },
        {
            "endOffset": 41453,
            "parents": [],
            "secId": "s0065",
            "sentence": "Following the second MenACWY-TT dose, \u226598.0% of toddlers had rSBA titres \u22651:8 and \u226595.3% hSBA titres \u22651:4.",
            "startOffset": 41347,
            "title": "Discussion"
        },
        {
            "endOffset": 31684,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methods"
                }
            ],
            "secId": "s0025",
            "sentence": "Parents recorded solicited local and general symptoms during a 4-day (days 0\u20133) and unsolicited adverse events (AEs) during a 31-day (days 0\u201330) post-vaccination period, using diary cards.",
            "startOffset": 31496,
            "title": "Assessments"
        },
        {
            "endOffset": 48027,
            "parents": [],
            "secId": "s0085",
            "sentence": "MvdW declared stock ownership in the GSK group of companies.",
            "startOffset": 47967,
            "title": "Conflict of interest"
        },
        {
            "endOffset": 33674,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methods"
                }
            ],
            "secId": "s0030",
            "sentence": "All analyses were performed using the Statistical Analysis System software (SAS Institute Inc., Cary, United States).",
            "startOffset": 33557,
            "title": "Statistical analyses"
        },
        {
            "endOffset": 32194,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methods"
                }
            ],
            "refoffsets": {
                "b0070": {
                    "endOffset": 32183,
                    "startOffset": 32179
                }
            },
            "secId": "s0030",
            "sentence": "The power to assess the confirmatory objectives, calculated based on rSBA response rates previously observed for MenACWY-TT in toddlers [14], was \u226599%.",
            "startOffset": 32043,
            "title": "Statistical analyses"
        },
        {
            "endOffset": 44929,
            "parents": [],
            "secId": "s0065",
            "sentence": "Finally, the results of exploratory analyses presented in this manuscript should be interpreted cautiously as they were performed without accounting for multiplicity.",
            "startOffset": 44763,
            "title": "Discussion"
        },
        {
            "endOffset": 37505,
            "parents": [
                {
                    "id": "s0035",
                    "title": "Results"
                }
            ],
            "secId": "s0060",
            "sentence": "Following MenACWY-TT administration, the most common local symptom was redness, reported in 34.2%, 37.4% and 37.1% of toddlers in the ACWY_1, ACWY_2 and Co-ad groups, respectively, post-dose 1, and 33.9% of toddlers in group ACWY_2, post-dose 2.",
            "startOffset": 37260,
            "title": "Safety"
        },
        {
            "endOffset": 31307,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methods"
                }
            ],
            "refoffsets": {
                "b0115": {
                    "endOffset": 31156,
                    "startOffset": 31152
                },
                "b0120": {
                    "endOffset": 31240,
                    "startOffset": 31236
                },
                "b0125": {
                    "endOffset": 31281,
                    "startOffset": 31277
                }
            },
            "secId": "s0025",
            "sentence": "Immune responses to MenACWY-TT were evaluated using rSBA and hSBA assays [23] and to PCV13 antigens by both 22F-inhibition enzyme-linked immunosorbent assay [24] and opsonophagocytic activity assay [25], as detailed in Table S1.",
            "startOffset": 31079,
            "title": "Assessments"
        },
        {
            "endOffset": 45309,
            "parents": [],
            "secId": "s0070",
            "sentence": "Further follow-up will allow to determine if the higher responses for MenW and MenY observed after the second dose result in improved antibody persistence.",
            "startOffset": 45154,
            "title": "Conclusions"
        },
        {
            "endOffset": 47705,
            "parents": [],
            "secId": "s0085",
            "sentence": "PR\u2019s institution receives funding for investigator led studies from industry (including Pfizer and GSK).",
            "startOffset": 47601,
            "title": "Conflict of interest"
        },
        {
            "endOffset": 44082,
            "parents": [],
            "secId": "s0065",
            "sentence": "The incidence of local AEs was generally lower following MenACWY-TT compared to PCV13 vaccination, despite the higher content of carrier protein in MenACWY-TT.",
            "startOffset": 43923,
            "title": "Discussion"
        },
        {
            "endOffset": 38477,
            "parents": [
                {
                    "id": "s0035",
                    "title": "Results"
                }
            ],
            "secId": "s0060",
            "sentence": "For 5.4\u20137.6% of participants across all groups, the AEs were considered causally related to vaccination, with diarrhoea, vomiting, pyrexia, rash and bruise at injection site being the most common.",
            "startOffset": 38281,
            "title": "Safety"
        },
        {
            "endOffset": 45878,
            "parents": [],
            "secId": "s0075",
            "sentence": "GlaxoSmithKline Biologicals SA was the funding source and was involved in all stages of the study conduct and analysis as well as the development of the manuscript and its approval for submission.",
            "startOffset": 45682,
            "title": "Funding"
        },
        {
            "endOffset": 26278,
            "parents": [],
            "refoffsets": {
                "b0020": {
                    "endOffset": 26277,
                    "startOffset": 26272
                },
                "b0025": {
                    "endOffset": 26277,
                    "startOffset": 26272
                },
                "b0030": {
                    "endOffset": 26277,
                    "startOffset": 26272
                },
                "b0035": {
                    "endOffset": 26277,
                    "startOffset": 26272
                }
            },
            "secId": "s0005",
            "sentence": "Increases in MenW incidence have been reported recently in the United Kingdom, South America and Australia [4\u20137].",
            "startOffset": 26165,
            "title": "Introduction"
        },
        {
            "endOffset": 42329,
            "parents": [],
            "refoffsets": {
                "b0085": {
                    "endOffset": 42328,
                    "startOffset": 42324
                }
            },
            "secId": "s0065",
            "sentence": "In the persistence study, differences in terms of percentages of children with MenW hSBA titres \u22651:4 were also significant at 5 years, but not at 3 years post-vaccination, with no significant differences observed for the other serogroups [17].",
            "startOffset": 42086,
            "title": "Discussion"
        },
        {
            "endOffset": 36976,
            "parents": [
                {
                    "id": "s0035",
                    "title": "Results"
                },
                {
                    "id": "s0045",
                    "title": "Immunogenicity"
                }
            ],
            "secId": "s0055",
            "sentence": "One month post-vaccination with PCV13, for each vaccine serotype, percentages of toddlers with antibody concentrations \u22650.35 \u03bcg/ml ranged between 79.0% and 100%, and antibody GMCs were comparable among the Co-ad and PCV13/ACWY groups (Table 4, Table S5).",
            "startOffset": 36722,
            "title": "Co-administration of MenACWY-TT and PCV13"
        }
    ],
    "docId": "S0264410X18301877",
    "metadata": {
        "asjc": [
            "1313",
            "2400",
            "2725",
            "2739",
            "3400"
        ],
        "authors": [
            {
                "email": "cutlandc@rmpru.co.za",
                "first": "Clare L.",
                "initial": "C.L.",
                "last": "Cutland"
            },
            {
                "email": "t.nolan@unimelb.edu.au",
                "first": "Terry",
                "initial": "T.",
                "last": "Nolan"
            },
            {
                "email": "scott.halperin@dal.ca",
                "first": "Scott A.",
                "initial": "S.A.",
                "last": "Halperin"
            },
            {
                "email": "zafer.kurugol@ege.edu.tr",
                "first": "Zafer",
                "initial": "Z.",
                "last": "Kurugol"
            },
            {
                "email": "kahmed@setshaba.org.za",
                "first": "Khatija",
                "initial": "K.",
                "last": "Ahmed"
            },
            {
                "email": "kirsten.perrett@rch.org.au",
                "first": "Kirsten P.",
                "initial": "K.P.",
                "last": "Perrett"
            },
            {
                "email": "peter.richmond@uwa.edu.au",
                "first": "Peter",
                "initial": "P.",
                "last": "Richmond"
            },
            {
                "email": "helen.marshall@adelaide.edu.au",
                "first": "Helen S.",
                "initial": "H.S.",
                "last": "Marshall"
            },
            {
                "email": "mceyhan@hacettepe.edu.tr",
                "first": "Mehmet",
                "initial": "M.",
                "last": "Ceyhan"
            },
            {
                "email": "devi.cancer@gmail.com",
                "first": "Devayani",
                "initial": "D.",
                "last": "Kolhe"
            },
            {
                "email": "mhezareh@yahoo.com",
                "first": "Marjan",
                "initial": "M.",
                "last": "Hezareh"
            },
            {
                "email": "marie.x.van-der-wielen@gsk.com",
                "first": "Marie",
                "initial": "M.",
                "last": "Van Der Wielen"
            }
        ],
        "doi": "10.1016/j.vaccine.2018.02.013",
        "firstpage": "1908",
        "issn": "0264410X",
        "lastpage": "1916",
        "openaccess": "Full",
        "pub_year": 2018,
        "subjareas": [
            "BIOC",
            "IMMU",
            "MEDI",
            "VETE"
        ],
        "title": "Immunogenicity and safety of one or two doses of the quadrivalent meningococcal vaccine MenACWY-TT given alone or with the 13-valent pneumococcal conjugate vaccine in toddlers: A phase III, open-label, randomised study"
    }
}